Our location
mRNA/LNP development and manufacturing in Geleen
At our Geleen site in the Netherlands, Lonza supports mRNA/LNP process development, analytical development and clinical cGMP manufacturing. The expanded facility includes more than 30,000 square feet of laboratory, cGMP manufacturing and office space, supporting non-GMP product for formulation development and toxicology studies as well as cGMP product for early- and late-stage clinical trials.
Scaling lipid nanoparticle manufacturing can impact critical attributes like particle size, encapsulation efficiency, and reproducibility. As leading lipid manufacturers, we address these challenges by strictly controlling critical process parameters and applying proprietary scalable technologies to maintain consistent quality from the lab to commercial scale.
We monitor impurities including residual DNA template, double-stranded RNA, truncated transcripts, enzymes, and lipid-related degradation products. Our LNP encapsulation services include the process- and product-related testing that supports product safety and purity.